H.C. Wainwright analyst Andrew Fein raised the firm’s price target on Catalyst Pharmaceuticals (CPRX) to $35 from $30 and keeps a Buy rating on ...

Sadly, some of the strongest characters that stand out in the books didn't make it into any of the Harry Potter movies.

For branded drugmakers, the development of a pharmaceutical product approved by the Food and Drug Administration (FDA) all ...

Catalyst Pharmaceuticals settles patent litigation with Teva, delaying generic Firdapse launch until 2035. Legal actions against other defendants remain ongoing.

Catalyst stock gains 17% as it settles Firdapse patent litigation with Teva protecting the drug's exclusivity in the United ...

As India marks a decade of its Act East Policy, Odisha is a vital hub, with its grand shoreline, foundational ports, and its historic maritime ties across southeast Asia, to unlock opportunities and ...

Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing ...

Cat McCarrey I spent too long trying to puzzle out this week’s mystery pick. Here are the hints provided: It’s an Eighties ...

Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for ...